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Introduction
Polymorphisms in genes involved in antibody-dependent
cellular cytotoxicity and apoptosis have been associated
with inter-individual differences in the response to anti-
TNF agent infliximab in arthritides. TRAILR1 and
TNFR1A are two genes related to the extrinsic pathway
of apoptosis.
Aim
To evaluate the role of two polymorphisms (rs20575/
G36A and rs767455/C626G) in these genes in the sus-
ceptibility and pharmacogenetics of rheumatoid arthritis
(RA) and ankylosing spondylitis (AS) patients treated
with infliximab. Patients and Methods. TRAILR1 and
TNFR1 genotyping was performed in 138 patients (86 RA
and 52 AS), and in two groups of controls (158 for RA
and 182 for AS). A subset of 47 RA and 40 AS patients
was also studied for the association of this polymorphism
with the response to infliximab treatment assessed by
EULAR and BASDAI criteria, respectively.
Results
No significant differences were observed between cases
and controls in the genotype and allele distribution of
TRAILR1 or TNFR1A polymorphisms for both diseases,
though a tendency for a RA protective role of TNFR1A
AA genotype was observed (29.8% vs. 38.2%; p=0.1172).
TRAILR1 G allele was associated with poor response
after 3 month of infliximab treatment (G: 32.4% vs.
C 14%; p=0.044). Similar results were observed for AS, as
the prevalence of non-responders was significantly lower
in C carriers both, at 3 months (21.4% vs. 83.3%;
p=0.003) and 6 months (11.5% vs. 50%; p=0.029) of inflix-
imab treatment. No significant differences were observed
for TNFR1 polymorphism in terms of response.
Conclusions
This work provides the first evidence that rs20575 poly-
morphism in TRAILR1 seems to influence the response
to infliximab treatment both in RA and AS patients.
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